Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 134

1.

Anticancer effects of a non-narcotic opium alkaloid medicine, papaverine, in human glioblastoma cells.

Inada M, Shindo M, Kobayashi K, Sato A, Yamamoto Y, Akasaki Y, Ichimura K, Tanuma SI.

PLoS One. 2019 May 17;14(5):e0216358. doi: 10.1371/journal.pone.0216358. eCollection 2019.

2.

Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.

Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R, Tamura K, Narita Y, Hamada A, Masutomi K, Ichimura K.

Cancer Sci. 2019 May 17. doi: 10.1111/cas.14067. [Epub ahead of print]

3.

High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene.

Kurozumi K, Nakano Y, Ishida J, Tanaka T, Doi M, Hirato J, Yoshida A, Washio K, Shimada A, Kohno T, Ichimura K, Yanai H, Date I.

Brain Tumor Pathol. 2019 Apr 22. doi: 10.1007/s10014-019-00345-y. [Epub ahead of print]

PMID:
31011918
4.

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.

Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP.

Clin Cancer Res. 2019 Apr 11. doi: 10.1158/1078-0432.CCR-18-4144. [Epub ahead of print]

PMID:
30975663
5.

Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.

Sasaki A, Hirato J, Hirose T, Fukuoka K, Kanemura Y, Hashimoto N, Kodama Y, Ichimura K, Sakamoto H, Nishikawa R.

Brain Tumor Pathol. 2019 Apr;36(2):92-101. doi: 10.1007/s10014-019-00338-x. Epub 2019 Mar 30.

PMID:
30929114
6.

TERT promoter mutation as a diagnostic marker for diffuse gliomas.

Ichimura K.

Neuro Oncol. 2019 Mar 18;21(4):417-418. doi: 10.1093/neuonc/noz025. No abstract available.

PMID:
30852620
7.

Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors.

Sonoda Y, Yokoo H, Tanaka S, Kinoshita M, Nakada M, Nishihara H; committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology.

Brain Tumor Pathol. 2019 Apr;36(2):56-62. doi: 10.1007/s10014-019-00337-y. Epub 2019 Mar 7.

PMID:
30847711
8.

Protein Phosphatases-A Touchy Enemy in the Battle Against Glioblastomas: A Review.

Tomiyama A, Kobayashi T, Mori K, Ichimura K.

Cancers (Basel). 2019 Feb 19;11(2). pii: E241. doi: 10.3390/cancers11020241. Review.

9.

Signal transduction pathways and resistance to targeted therapies in glioma.

Tomiyama A, Ichimura K.

Semin Cancer Biol. 2019 Jan 24. pii: S1044-579X(18)30098-1. doi: 10.1016/j.semcancer.2019.01.004. [Epub ahead of print] Review.

PMID:
30685341
10.

Genome-wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma.

Nakamura T, Fukuoka K, Nakano Y, Yamasaki K, Matsushita Y, Yamashita S, Ikeda J, Udaka N, Tanoshima R, Shiba N, Tateishi K, Yamanaka S, Yamamoto T, Hirato J, Ichimura K.

Cancer Sci. 2019 Feb;110(2):828-832. doi: 10.1111/cas.13903. Epub 2019 Jan 4.

11.

Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.

Fukuoka K, Kanemura Y, Shofuda T, Fukushima S, Yamashita S, Narushima D, Kato M, Honda-Kitahara M, Ichikawa H, Kohno T, Sasaki A, Hirato J, Hirose T, Komori T, Satomi K, Yoshida A, Yamasaki K, Nakano Y, Takada A, Nakamura T, Takami H, Matsushita Y, Suzuki T, Nakamura H, Makino K, Sonoda Y, Saito R, Tominaga T, Matsusaka Y, Kobayashi K, Nagane M, Furuta T, Nakada M, Narita Y, Hirose Y, Ohba S, Wada A, Shimizu K, Kurozumi K, Date I, Fukai J, Miyairi Y, Kagawa N, Kawamura A, Yoshida M, Nishida N, Wataya T, Yamaoka M, Tsuyuguchi N, Uda T, Takahashi M, Nakano Y, Akai T, Izumoto S, Nonaka M, Yoshifuji K, Kodama Y, Mano M, Ozawa T, Ramaswamy V, Taylor MD, Ushijima T, Shibui S, Yamasaki M, Arai H, Sakamoto H, Nishikawa R, Ichimura K; Japan Pediatric Molecular Neuro-Oncology Group (JPMNG).

Acta Neuropathol Commun. 2018 Dec 4;6(1):134. doi: 10.1186/s40478-018-0630-1.

12.

Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.

Nakano Y, Tomiyama A, Kohno T, Yoshida A, Yamasaki K, Ozawa T, Fukuoka K, Fukushima H, Inoue T, Hara J, Sakamoto H, Ichimura K.

Brain Tumor Pathol. 2019 Jan;36(1):14-19. doi: 10.1007/s10014-018-0330-3. Epub 2018 Oct 22. Review.

PMID:
30350109
13.

Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.

Yoshida A, Satomi K, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Hiraoka N, Narita Y, Ichimura K.

Histopathology. 2019 Jan;74(2):350-354. doi: 10.1111/his.13756. Epub 2018 Dec 5.

PMID:
30221786
14.

Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas.

Arita H, Kinoshita M, Kawaguchi A, Takahashi M, Narita Y, Terakawa Y, Tsuyuguchi N, Okita Y, Nonaka M, Moriuchi S, Takagaki M, Fujimoto Y, Fukai J, Izumoto S, Ishibashi K, Nakajima Y, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y, Mano M, Mori K, Ichimura K, Kanemura Y.

Sci Rep. 2018 Aug 6;8(1):11773. doi: 10.1038/s41598-018-30273-4.

15.

Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.

Yamauchi T, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Kitagawa Y, Kondo E, Tsushita N, Satomi K, Yoshida A, Ichimura K, Narita Y.

Brain Tumor Pathol. 2018 Jul;35(3):148-158. doi: 10.1007/s10014-018-0321-4. Epub 2018 Jun 19.

PMID:
29922974
16.

Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.

Yamamoto Y, Sasaki N, Kumagai K, Takeuchi S, Toyooka T, Otani N, Wada K, Narita Y, Ichimura K, Namba H, Mori K, Tomiyama A.

Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):296-302. doi: 10.2176/nmc.ra.2018-0040. Epub 2018 Jun 13. Review.

17.

The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas.

Miyazaki M, Otomo R, Matsushima-Hibiya Y, Suzuki H, Nakajima A, Abe N, Tomiyama A, Ichimura K, Matsuda K, Watanabe T, Ochiya T, Nakagama H, Sakai R, Enari M.

Cell Death Discov. 2018 May 10;4:56. doi: 10.1038/s41420-018-0059-0. eCollection 2018.

18.

Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.

Miki S, Imamichi S, Fujimori H, Tomiyama A, Fujimoto K, Satomi K, Matsushita Y, Matsuzaki S, Takahashi M, Ishikawa E, Yamamoto T, Matsumura A, Mukasa A, Nishikawa R, Masutomi K, Narita Y, Masutani M, Ichimura K.

Cancer Sci. 2018 Jul;109(7):2275-2285. doi: 10.1111/cas.13637. Epub 2018 Jun 19.

19.

IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.

Otani R, Uzuka T, Higuchi F, Matsuda H, Nomura M, Tanaka S, Mukasa A, Ichimura K, Kim P, Ueki K.

Cancer Sci. 2018 Jul;109(7):2327-2335. doi: 10.1111/cas.13635. Epub 2018 Jun 15.

20.

Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.

Masui K, Komori T, Kato Y, Masutomi K, Ichimura K, Ogasawara S, Kaneko MK, Oki H, Suzuki H, Nitta M, Maruyama T, Muragaki Y, Kawamata T, Sawada T, Shibata N.

Biomed Res Int. 2018 Mar 5;2018:7945845. doi: 10.1155/2018/7945845. eCollection 2018.

Supplemental Content

Loading ...
Support Center